Researchers have identified a molecule that can be used to expand stem cells from cord blood, according to a study in The Lancet Haematology. The molecule UM171 can help to expand the baseline CD34 cell counts of a unit of cord blood by an average of 35 times, lead author Sandra Cohen said.
Andelyn Biosciences is a biotech spun off by Nationwide Children's Hospital that will focus on manufacturing gene therapy components for use in clinical trials. "Commercial-scale manufacturing represents one of the next significant barriers to the continued development of the field," said Dennis Durbin, chief scientific officer of Nationwide's Abigail Wexner Research Institute.
Astellas and Adaptimmune have partnered to develop T-cell receptor and allogeneic chimeric antigen receptor T-cell therapies. Adaptimmune will be paid $50 million plus $7.5 million per year to fund the research, in addition to potential milestone payments.
The European Medicines Agency has agreed to allow Emergent BioSolutions to move toward a Phase III trial of its chikungunya virus vaccine candidate. A Phase II trial of the National Institute of Allergy and Infectious Diseases-licensed vaccine is being conducted in the US.
Chimeric antigen receptor-T cell therapy continues to expand and show potential in changing the clinical course of diseases, writes pathology and immunology assistant professor Suzanne Thibodeaux of Washington University in St. Louis School of Medicine. Thibodeaux outlines the steps clinical laboratorians should consider to improve clinical management while ensuring patients receive optimal care throughout the process of CAR-T cell therapy.
The FDA has granted breakthrough device designation to KDx Diagnostics' URO17 test that detects recurrent bladder cancer from urine samples. An initial study showed that the non-invasive test yielded 100% sensitivity and 96% specificity in identifying recurrent bladder cancer.
The CDC estimates there have been 9.7 million flu cases, 87,000 flu-related hospitalizations and 4,800 flu-related fatalities, including 32 pediatric deaths, so far this season. As of the week ending Jan. 4, high flu activity was reported in 33 states, while widespread flu activity was reported in 46 states.
Researchers found that bacteria that had developed resistance to one antibiotic were less susceptible to other antibiotics, suggesting that combining several antibiotics could result in increased resistance, according to a study in the journal Science. The findings were based on lab studies of bacteria taken from two patients with persistent blood infections.
The FDA has given Applied BioCode 510(k) clearance for its BioCode Respiratory Pathogen Panel, allowing it to run on the BioCode MDx-3000 system. The panel detects Bordetella pertussis, Chlamydia pneumoniae, influenza A and subtypes H1, H3 and H1N1 2009pdm, influenza B and other common viruses and bacteria in nasopharyngeal swabs.
- Page 1